FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received notification from the United States Patent and Trademark Office of the allowance for issuance of two new patents. One patent is entitled “Methods of Ventricular Arrhythmia Localization Using a 3D Model”. This patent is another milestone of add ...

FORT MILL, S.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received the first purchase order from a hospital in Croatia after winning a competitive tender bid. As previously announced, Dubrava Hospital completed an evaluation before placing VIVO into the bid process for purchase approval. The biding process al ...

Company Overview - Catheter Precision, Inc. is a U.S.-based medical device company focused on developing advanced products for the cardiac electrophysiology market [2] - The company aims to improve the treatment of cardiac arrhythmias through innovative technology and collaboration with physicians [2] Upcoming Special Meeting - A special meeting of stockholders is scheduled for October 10, 2025, with a record date of September 10, 2025 [1] - The company seeks stockholder approval to amend its Certificate of Incorporation to increase the authorized shares of common stock and to appoint WithumSmith+Brown, PC as the independent auditor for fiscal year 2026 [1] Proxy Materials - Catheter Precision plans to file proxy materials with the U.S. Securities and Exchange Commission (SEC) related to the solicitation of proxies for the special meeting [5] - Stockholders can access the Preliminary and Definitive Proxy Statement and other related documents for free on the SEC's website or the company's website [5] Participants in Solicitation - The company, its directors, and certain executive officers may be considered "participants" in the proxy solicitation for the special meeting [6] - Information regarding these participants and their interests will be included in the Proxy Statement and related materials [6]

First European Purchase Order for LockeT ReceivedFort Mill, SC, Sept. 02, 2025 (GLOBE NEWSWIRE) -- – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced the introduction of LockeT in Italy. Following the first successful procedures and clinical acceptance in France and Germany a successful product evaluation was completed in Italy. The first procedures in Italy were perfo ...

Core Insights - Catheter Precision, Inc. has successfully completed the first LockeT procedures in France, marking a significant step in the adoption of its cardiac electrophysiology technologies in Europe [1][2] - The procedures were conducted at CHU Rennes, which is also a commercial partner for the company's VIVO product line [2] - The LockeT device is designed to improve procedural efficiency and patient outcomes following cardiac ablation procedures, indicating a strong market need in Europe [3] Product Information - LockeT is a suture retention device aimed at assisting in wound closure after percutaneous venous punctures, classified as a Class 1 device with FDA registration and CE Mark approval [4] - VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system that helps identify the origin of ventricular arrhythmias before procedures, thus streamlining workflow and reducing procedure time; it has also received FDA marketing clearance and CE Mark [5] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [6]

Core Viewpoint - Catheter Precision, Inc. has received a new patent for its VIVO technology, enhancing its intellectual property portfolio and supporting its mission to improve non-invasive identification of ventricular arrhythmias [1][2]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [4]. Product Information - VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system that helps physicians identify the origin of ventricular arrhythmias before procedures, thereby improving workflow and reducing procedure time. It has received marketing clearance from the U.S. FDA and holds the CE Mark [3]. Patent Significance - The newly granted patent titled "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model" allows the company to further advance its identification methods, providing essential information to physicians for successful patient treatment [1][2].

Core Insights - Catheter Precision, Inc. has initiated the LockeT Compare Study, enrolling its first three patients, aimed at evaluating the safety profile of the LockeT suture retention device [1][2] - The study will enroll up to 100 patients and compare the LockeT device with internal closure devices, focusing on reducing groin complications post-cardiac catheter procedures [2] - The LockeT device has shown clinical data indicating safety, effectiveness, and cost reduction without altering hospital practices [2][3] Company Overview - Catheter Precision is a U.S.-based medical device company dedicated to improving cardiac arrhythmia treatment through innovative technology and collaboration with physicians [4] - The LockeT device is a Class 1 device registered with the FDA and has received CE Mark approval, designed for wound closure after percutaneous venous punctures [3][4]

Core Insights - Catheter Precision, Inc. has received registration and approval for its LockeT product in the United Kingdom, which is a significant step for the company to launch sales in the UK market [1] - The LockeT product, a suture retention device, previously received CE Mark approval for European distribution in May 2025 [1][4] - The partnership with HC21, a UK-based distributor, aims to enhance market access for LockeT, leveraging HC21's annual revenue of €180 million and extensive network in the medical device sector [2] Product Details - LockeT is designed to assist in wound closure after percutaneous venous punctures and is classified as a Class 1 device registered with the FDA [4] - The product's intuitive design is expected to improve patient comfort and recovery, facilitating earlier discharge after cardiac procedures [3] Market Impact - The introduction of LockeT is aligned with the NHS's efforts to reduce waiting lists, which recently saw its first reduction in 17 years, potentially allowing clinicians to deliver more treatments efficiently [3] - Catheter Precision aims to collaborate closely with UK healthcare providers to maximize the benefits of LockeT for patients across the nation [3]

Core Points - Catheter Precision, Inc. has executed a 1-for-19 reverse stock split effective August 15, 2025, with trading continuing under the symbol "VTAK" on a split-adjusted basis [1][2] - The reverse stock split will reduce the number of issued shares from approximately 23,316,520 to about 1,657,640 shares [4] - Stockholders will not receive fractional shares; instead, they will receive a pro rata portion of the net proceeds from the sale of fractional shares [3] Company Details - The reverse stock split will not change the par value per share and will affect all stockholders uniformly [2][3] - Stockholders holding shares in brokerage accounts should direct inquiries to their brokers, while all stockholders of record can contact the Company's transfer agent for assistance [4] - Additional information regarding the reverse stock split is available in the Company's definitive proxy statement filed with the SEC [5]

Core Insights - Catheter Precision, Inc. has successfully completed the first LockeT cases in Germany, specifically at Zentralklinik Bad Berka, one of the largest hospitals in Thuringia [1] - The physician team has performed 10 successful cases using the LockeT device, showcasing its versatility across various sheath sizes from 6F to 17Fr [2] - The CEO of Catheter Precision highlighted Germany as a significant market in Europe, emphasizing the potential for expanding the use of LockeT in other centers within the country [3] Product Information - LockeT is a suture retention device designed for wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [4] - The company focuses on developing innovative solutions for cardiac arrhythmias and collaborates with physicians to advance its product offerings [5]